BRIEF-Organon Appoints Company Executive Joseph Morrissey As Interim CEO And Board Chair Carrie Cox As Executive Chair Announces Results Of Audit Committee Investigation

Reuters
2025/10/27
BRIEF-Organon Appoints Company Executive Joseph Morrissey As Interim CEO And Board Chair Carrie Cox As Executive Chair Announces Results Of Audit Committee Investigation

Organon & Co OGN.N:

  • ORGANON APPOINTS COMPANY EXECUTIVE JOSEPH MORRISSEY AS INTERIM CEO AND BOARD CHAIR CARRIE COX AS EXECUTIVE CHAIR; ANNOUNCES RESULTS OF AUDIT COMMITTEE INVESTIGATION

  • ORGANON & CO - APPOINTS JOSEPH MORRISSEY AS INTERIM CEO

  • ORGANON & CO - KEVIN ALI RESIGNS AS CEO AND BOARD MEMBER

  • ORGANON: INVESTIGATION FOUND THAT SOME WHOLESALERS IN US WERE ASKED TO BUY MORE NEXPLANON THAN NEEDED AT END OF Q4 2022, Q3 & Q4 2024, Q1, Q2, Q3 2025

  • ORGANON: INVESTIGATION FOUND NEXPLANON SALES REPRESENTED LESS THAN 1% OF CO'S CONSOLIDATED REVENUE FOR YEAR ENDED DEC 31, 2022 OR DEC 31, 2024

  • ORGANON & CO: FINDINGS TO DATE DO NOT NECESSITATE A RESTATEMENT OR REVISION TO ANY PREVIOUSLY ISSUED FINANCIAL STATEMENTS

  • ORGANON & CO: TAKING REMEDIAL ACTIONS TO IMPROVE ITS FINANCIAL CONTROLS AND ADDRESS ANY MATERIAL WEAKNESSES

  • ORGANON & CO: IN CONNECTION WITH INVESTIGATION, TERMINATED EMPLOYMENT OF HEAD OF U.S. COMMERCIAL & GOVERNMENT AFFAIRS

  • ORGANON & CO: THERE HAS BEEN NO FINDING THAT CFO WAS AWARE OF IMPROPER WHOLESALER SALES PRACTICES

  • ORGANON & CO: INITIATING A SEARCH FOR A PERMANENT CEO, INCLUDING BOTH INTERNAL AND EXTERNAL CANDIDATES

  • ORGANON & CO: IMPROPER NEXPLANON SALES PRACTICES ENABLED CO TO MEET GUIDANCE AND/OR CERTAIN EXTERNAL REVENUE EXPECTATIONS

Source text: ID:nBw6cK19Ha

Further company coverage: OGN.N

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10